NCT06943755 2026-04-17
STELLAR-311
Exelixis
Phase 2/3 Recruiting
Clinical Trials
20 trialsNCT06947928 2026-04-17
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting
NCT04534205 2026-04-15
AHEAD-MERIT
BioNTech SE
Phase 2/3 Recruiting
NCT04787744 2026-04-08
VA STARPORT
VA Office of Research and Development
Phase 2/3 Recruiting
NCT06989437 2026-04-08
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
Phase 2/3 Recruiting
NCT06506955 2026-04-03
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
NCT07509398 2026-04-03
FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer
Shanghai 10th People's Hospital
Phase 2/3 Not yet recruiting
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune Inc.
Phase 2/3 Recruiting
NCT07426094 2026-03-23
PRO-BOOST-N
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Phase 2/3 Recruiting
NCT02491632 2026-03-18
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
Phase 2/3 Active not recruiting
NCT03021486 2026-03-18
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
M.D. Anderson Cancer Center
Phase 2/3 Active not recruiting
NCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT03927885 2026-02-19
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
Phase 2/3 Active not recruiting
NCT07321847 2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3 Not yet recruiting
NCT03743649 2025-12-26
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
M.D. Anderson Cancer Center
Phase 2/3 Active not recruiting
NCT06783140 2025-12-05
PLATINUM-CAN
University Health Network, Toronto
Phase 2/3 Recruiting
NCT06100367 2025-12-02
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
Changi General Hospital
Phase 2/3 Active not recruiting
NCT06697301 2025-11-12
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Eikon Therapeutics
Phase 2/3 Recruiting
NCT01861938 2025-10-02
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Hadassah Medical Organization
Phase 2/3 Withdrawn
NCT00922974 2025-04-29
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
Radiation Therapy Oncology Group
Phase 2/3 Completed